J. Hearn

发表

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.

M. Terris, M. Cooperberg, P. Carroll, 2020, JAMA oncology.

Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications

Virginia E Rogers, Prasad R. Shankar, X. Shao, 2018, EJNMMI Research.

Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

S. Jolly, V. Murthy, R. T. Ten Haken, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in prostate orientation due to removal of a Foley catheter

W. Jackson, J. Hearn, M. Schipper, 2018, Medical physics.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

R. Hannan, R. Mehra, R. Dess, 2018, European urology oncology.

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.

A. Kishan, R. Mehra, H. Sandler, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

David C. Miller, S. Jolly, R. Mehra, 2018, European urology.

A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients

T. Johnson, J. Hearn, D. Spratt, 2021, The Journal of Nuclear Medicine.

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.

R. DiPaola, C. Reddy, B. Hobbs, 2020, JAMA oncology.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.

Sharyn I. Katz, D. Yankelevitz, Nofisat Ismaila, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy

R. Mehra, C. Catton, R. Dess, 2019, The Journal of urology.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

A. Kishan, M. Cooperberg, R. Mehra, 2019, International journal of radiation oncology, biology, physics.

TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results

T. Skolarus, L. Arab, R. Dunn, 2022, Cancer.

AWARD NUMBER: W81XWH-15-1-0503 TITLE: Germline Variation in HSD3B1 as a Novel Biomarker in Prostate Cancer PRINCIPAL INVESTIGATOR: Jason Hearn, MD CONTRACTING ORGANIZATION: University of Michigan

J. Hearn, 2017 .

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer

P. Kantoff, J. Hearn, M. Pomerantz, 2017, JAMA oncology.

Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial

Hao Wang, P. Tran, J. Hearn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Focal radiation for oligometastatic castration-resistant prostate cancer (FORCE): A phase II randomized trial.

David C. Smith, S. Tomlins, J. Hearn, 2019, Journal of Clinical Oncology.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)

Hao Wang, D. Song, P. Tran, 2019, BMC Cancer.

HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

D. Tindall, C. Magi-Galluzzi, C. Reddy, 2016, The Lancet. Oncology.

Adverse events in radiation oncology: A case series from wake up safe, the pediatric anesthesia quality improvement initiative

J. Hearn, D. Spratt, R. Christensen, 2019, Paediatric anaesthesia.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features

A. Niemierko, A. Zietman, M. Anscher, 2018, JAMA oncology.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

A. Zietman, M. Anscher, J. Hearn, 2017, European urology.

A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

S. Jolly, Dafydd G. Thomas, M. Tewari, 2019, International journal of radiation oncology, biology, physics.

Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

S. Jolly, P. Boonstra, R. T. Ten Haken, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Serum MicroRNA Signature Predicts Response to High-Dose Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer.

S. Jolly, M. Tewari, R. T. Ten Haken, 2018, International journal of radiation oncology, biology, physics.

The Special Medical Physics Consult Process for Reirradiation Patients

J. Hearn, D. Spratt, C. Mayo, 2019, Advances in radiation oncology.

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization

G. Merrick, P. McLaughlin, R. Dess, 2019, American journal of clinical oncology.

Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.

J. Hearn, D. Spratt, J. Efstathiou, 2021, European urology oncology.

Megavolt bremsstrahlung measurements from linear induction accelerators demonstrate possible use as a FLASH radiotherapy source to reduce acute toxicity

J. Hearn, G. Caporaso, S. Sampayan, 2021, Scientific Reports.

Anatomical patterns of recurrence following biochemical relapse after post‐prostatectomy salvage radiation therapy: a multi‐institutional study

David C. Miller, R. Hannan, M. Folkert, 2017, BJU international.

Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up

S. Tomlins, R. Mehra, H. Sandler, 2016, Prostate Cancer and Prostatic Diseases.

A Comparison of Long-Term Treatment-Related Toxicities Between Moderately Hypofractionated and Conventionally Fractionated Radiation Therapy for Localized Prostate Cancer

J. Ciezki, C. Reddy, J. Hearn, 2014 .

HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.

R. DiPaola, C. Reddy, B. Hobbs, 2019, Journal of Clinical Oncology.

Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.

J. Hearn, T. Djemil, G. Videtic, 2014, International journal of radiation oncology, biology, physics.

D. Song, P. Tran, J. Hearn, 2019, BMC Cancer.

A Comprehensive Assessment of 68 Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients

J. Hearn, D. Spratt, J. Czernin, 2022 .

Serum microRNA Signature Predicts Response to High-dose Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer

S. Jolly, J. Hayman, R. Dess, 2017 .

Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients.

M. Zelefsky, H. Scher, J. Hearn, 2019, Journal of Clinical Oncology.